Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | CETP | P11597 | 2/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13693039 | 0.91 | GPR119 (0.49) | PIK3CAGPR119CETPCHEK2TBK1 | |
| SCHEMBL4111925 | 0.86 | GPR119 (0.49) | GPR119CETPCHEK2TBK1IKBKE | |
| SCHEMBL13602338 | 0.84 | GPR119 (0.56) | PIK3CAGPR119CETPCHEK2 | |
| SCHEMBL13602326 | 0.83 | GPR119 (0.51) | GPR119CETPCHEK2TBK1 | |
| SCHEMBL14640891 | 0.83 | GPR119 (0.53) | GPR119CETPCHEK2TBK1 | |
| SCHEMBL13602311 | 0.83 | GPR119 (0.51) | PIK3CAGPR119CETPCHEK2 | |
| SCHEMBL4102957 | 0.82 | GPR119 (0.56) | GPR119CETPTBK1IKBKE | |
| SCHEMBL12548315 | 0.82 | GPR119 (0.57) | GPR119CETP | |
| SCHEMBL4412797 | 0.81 | GPR119 (0.57) | GPR119CETPCHEK2 | |
| SCHEMBL4418527 | 0.81 | GPR119 (0.58) | GPR119CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | GPR119, GCGR, GPR27 | PIK3CA 1869/4885GPR119 1/4885CETP 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.